A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma
文献类型：期刊论文
| 作者 | Luo, Ping2,3; Yin, Peiyuan2; Hua, Rui4; Tan, Yexiong5; Li, Zaifang2,3; Qiu, Gaokun6; Yin, Zhenyu7; Xie, Xingwang1; Wang, Xiaomei4; Chen, Wenbin8 |
| 刊名 | HEPATOLOGY
 |
| 出版日期 | 2018-02-01 |
| 卷号 | 67期号:2页码:662-675 |
| ISSN号 | 0270-9139 |
| DOI | 10.1002/hep.29561 |
| 文献子类 | Article |
| 英文摘要 | Hepatocellular carcinoma (HCC) is the third most lethal cancer worldwide. The lack of effective biomarkers for the early detection of HCC results in unsatisfactory curative treatments. Here, metabolite biomarkers were identified and validated for HCC diagnosis. A total of 1,448 subjects, including healthy controls and patients with chronic hepatitis B virus infection, liver cirrhosis, and HCC, were recruited from multiple centers in China. Liquid chromatography-mass spectrometry-based metabolomics methods were used to characterize the subjects' serum metabolic profiles and to screen and validate the HCC biomarkers. A serum metabolite biomarker panel including phenylalanyl-tryptophan and glycocholate was defined. This panel had a higher diagnostic performance than did -fetoprotein (AFP) in differentiating HCC from a high-risk population of cirrhosis, such as an area under the receiver-operating characteristic curve of 0.930, 0.892, and 0.807 for the panel versus 0.657, 0.725, and 0.650 for AFP in the discovery set, test set, and cohort 1 of the validation set, respectively. In the nested case-control study, this panel had high sensitivity (range 80.0%-70.3%) to detect preclinical HCC, and its combination with AFP provided better risk prediction of preclinical HCC before clinical diagnosis. Besides, this panel showed a larger area under the receiver-operating characteristic curve than did AFP (0.866 versus 0.682) to distinguish small HCC, and 80.6% of the AFP false-negative patients with HCC were correctly diagnosed using this panel in the test set, which was corroborated by the validation set. The specificity and biological relevance of the identified biomarkers were further evaluated using sera from another two cancers and HCC tissue specimens, respectively. Conclusion: The discovered and validated serum metabolite biomarker panel exhibits good diagnostic performance for the early detection of HCC from at-risk populations. (Hepatology 2018;67:662-675). |
| WOS关键词 | PSEUDOTARGETED METABOLOMICS METHOD ; CHROMATOGRAPHY-MASS SPECTROMETRY ; HUMAN HEPATOCYTES ; GUT MICROBIOTA ; LIVER-DISEASE ; DISCOVERY ; ACID ; CARCINOGENESIS ; HOMEOSTASIS ; VALIDATION |
| WOS研究方向 | Gastroenterology & Hepatology |
| 语种 | 英语 |
| 出版者 | WILEY |
| WOS记录号 | WOS:000422694900022 |
| 源URL | [http://cas-ir.dicp.ac.cn/handle/321008/168712]  |
| 专题 | 大连化学物理研究所_中国科学院大连化学物理研究所 |
| 通讯作者 | Wu, Tangchun; Wang, Hongyang; Niu, Junqi; Xu, Guowang |
| 作者单位 | 1.Peking Univ, Peoples Hosp, Beijing, Peoples R China 2.Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China 4.Jilin Univ, Hosp 1, Dept Hepatol, Changchun 130021, Jilin, Peoples R China 5.Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200031, Peoples R China 6.Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, MOE Key Lab Environm & Hlth, Wuhan 430030, Hubei, Peoples R China 7.Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China 8.Shandong Univ, Shangdong Prov Hosp, Jinan, Shandong, Peoples R China |
| 推荐引用方式 GB/T 7714 | Luo, Ping,Yin, Peiyuan,Hua, Rui,et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma[J]. HEPATOLOGY,2018,67(2):662-675. |
| APA | Luo, Ping.,Yin, Peiyuan.,Hua, Rui.,Tan, Yexiong.,Li, Zaifang.,...&Xu, Guowang.(2018).A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.HEPATOLOGY,67(2),662-675. |
| MLA | Luo, Ping,et al."A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma".HEPATOLOGY 67.2(2018):662-675. |
入库方式： OAI收割
来源：大连化学物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。